Johnson & Johnson licenses novel inflammatory disease target from Mestag Therapeutics

Mestag Therapeutics, a biotech company harnessing new insights into fibroblast-immune interactions, has announced that Johnson & Johnson has exclusively licensed a novel, undisclosed target identified using Mestag’s Reversing Activated Fibroblast Technology (RAFT) platform under the multi-year target discovery collaboration announced in 2021.

“Activated fibroblasts play a key role in immune regulation in inflammatory disease, and Johnson & Johnson’s license of a new target identified during our collaboration exemplifies the capabilities of our target discovery platform,” said Susan Hill, PhD, Chief Executive Officer of Mestag.

Mestag’s unique and proprietary RAFT platform is purposely built to precisely model the role of pathogenic fibroblasts in disease, including its interactions with the immune system as well as other cell types, to identify novel targets.

Under the collaboration, Mestag applied the RAFT platform to model the biology of pathogenic fibroblast populations in human disease and used genetic knock out screening to identify new therapeutic targets.

Johnson & Johnson shall control, at its discretion, all potential development and commercialization of therapeutics directed against the licensed target. Mestag is eligible to receive future downstream payments.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news